Abstract
CCL18 is a CC chemokine ligand 18, which is produced by Tumor-Associated Macrophages (TAMs), that can stimulate the progressiveness, angiogenesis in breast cancer, as well as the underlying pathophysiological mechanisms and it was originally discovered as pulmonary and activation-regulated chemokine (PARC), dendritic cell (DC)-chemokine 1 (DC-CK1), alternative macrophage activation associated CC chemokine-1 (AMAC-1), and macrophage inflammatory protein-4 (MIP-4). The potential functional receptor of CCL18 protein is PITPNM3 that facilitates CCL18 effect and stimulates the intracellular calcium signaling pathway. Worldwide, Breast cancer (BCa) is one of the most common malignancies among the females in both developed and also developing county. This study mainly focused on the role of CCL18 in the production of breast tumor as well as in the invasiveness of breast cancer. The data here suggest that CCL18 protein play an important role in the development of breast tumor and also progression in breast cancer. This knowledge could be helpful for the proposal of new therapeutic approaches particularly in breast cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
